280 related articles for article (PubMed ID: 26603973)
1. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Honciuc M; Llorca PM
Encephale; 2015 Dec; 41(6):541-9. PubMed ID: 26603973
[TBL] [Abstract][Full Text] [Related]
2. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
Samalin L; Ben Gharbia M; Garnier M; Llorca PM
Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone in the treatment of schizophrenia: a critical evaluation.
Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone for schizophrenia.
Drug Ther Bull; 2015 Mar; 53(3):30-2. PubMed ID: 25765597
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
Citrome L; Weiden PJ; McEvoy JP; Correll CU; Cucchiaro J; Hsu J; Loebel A
CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868
[TBL] [Abstract][Full Text] [Related]
6. Lurasidone: a new treatment option for schizophrenia.
Owen RT
Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224
[TBL] [Abstract][Full Text] [Related]
7. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.
Awad G; Ng-Mak D; Rajagopalan K; Hsu J; Pikalov A; Loebel A
BMC Psychiatry; 2016 Jun; 16():176. PubMed ID: 27245981
[TBL] [Abstract][Full Text] [Related]
8. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
9. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.
Pompili M; Verzura C; Trovini G; Buscajoni A; Falcone G; Naim S; Nardella A; Sorice S; Baldessarini RJ; Girardi P
Expert Opin Drug Saf; 2018 Feb; 17(2):197-205. PubMed ID: 28902525
[TBL] [Abstract][Full Text] [Related]
10. Lurasidone : in the treatment of schizophrenia.
Sanford M
CNS Drugs; 2013 Jan; 27(1):67-80. PubMed ID: 23264146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
Goldman R; Loebel A; Cucchiaro J; Deng L; Findling RL
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):516-525. PubMed ID: 28475373
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
13. How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.
Macaluso M; Kazanchi H; Preskorn SH
Expert Opin Drug Metab Toxicol; 2015; 11(8):1317-27. PubMed ID: 26173973
[TBL] [Abstract][Full Text] [Related]
14. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.
Jaeschke RR; Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Styczeń K; Datka W
Pharmacol Rep; 2016 Aug; 68(4):748-55. PubMed ID: 27203278
[TBL] [Abstract][Full Text] [Related]
15. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
Corponi F; Fabbri C; Bitter I; Montgomery S; Vieta E; Kasper S; Pallanti S; Serretti A
Eur Neuropsychopharmacol; 2019 Sep; 29(9):971-985. PubMed ID: 31255396
[TBL] [Abstract][Full Text] [Related]
16. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A
J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189
[TBL] [Abstract][Full Text] [Related]
18. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
[TBL] [Abstract][Full Text] [Related]
19. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
Mattingly GW; Haddad PM; Tocco M; Xu J; Phillips D; Pikalov A; Loebel A
BMC Psychiatry; 2020 May; 20(1):199. PubMed ID: 32370778
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
